Fludarabine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
- Fludarabine
- Pharmacist Assessment Report
- Fludarabine: From Hematologic Malignancy Therapy to Plasma Cell Myeloma
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Cytotoxicity
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Fludarabine: From Hematologic Malignancy Therapy to Plasma Cell Myeloma
One-Sentence Summary
Fludarabine is a purine nucleoside analog chemotherapy drug, marketed in India in oral and injectable forms. The approved indication text was not available in the data compiled for this report. The TxGNN model predicts it may be useful for plasma cell myeloma, with 30 registered clinical trials and 20 publications linked to this prediction. Most of this evidence concerns fludarabine as a conditioning or lymphodepleting component, not as a stand-alone myeloma treatment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in the data compiled for this report |
| Predicted New Indication | Plasma cell myeloma |
| TxGNN Prediction Score | 0.9982 |
| Evidence Level | L2 |
| India Market Status | Listed in a compiled Indian medicine price dataset (9 of 9) – CDSCO approval status is not included in this data |
| Number of Listed Products | 9 (valid: 9) |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Fludarabine is a purine nucleoside analog that inhibits DNA synthesis and induces apoptosis in lymphoid cells. It is a recognised treatment in B-cell lymphoid malignancies such as chronic lymphocytic leukaemia, and plasma cell myeloma is a closely related B-cell cancer.
In myeloma, fludarabine is used mainly in two supportive roles. The first is lymphodepletion, together with cyclophosphamide, before BCMA-directed CAR-T therapy. The second is reduced-intensity conditioning before allogeneic stem cell transplant. A preclinical study (PMID 17976186) reported that fludarabine inhibited the RPMI8226 myeloma cell line in vitro and in vivo, which suggests some direct antimyeloma activity.
The prediction is therefore reasonable, but its practical meaning is narrow. The evidence supports fludarabine as part of transplant and cell-therapy regimens, not as a stand-alone antimyeloma drug.
Clinical Trial Evidence
The data include 30 registered trials. The table lists the 10 most relevant ones. Most test conditioning regimens or CAR-T products, and fludarabine is a backbone component rather than the variable under study.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01658319 | Phase 1 | Completed | 20 | Fludarabine plus methoxyamine (TRC102) in relapsed or refractory hematologic malignancies; fludarabine is the direct combination partner |
| NCT06045806 | Phase 3 | Active, not recruiting | 79 | Ide-cel plus lenalidomide maintenance vs lenalidomide alone in newly diagnosed myeloma (KarMMa-9); fludarabine is part of lymphodepletion |
| NCT07764978 | Phase 3 | Recruiting | 750 | BCMA/CD19 CAR-T consolidation (AZD0120) vs continuous standard therapy; fludarabine likely used for lymphodepletion |
| NCT03303950 | Phase 2 | Terminated | 6 | Busulfan, fludarabine, donor transplant and cyclophosphamide in myeloma or myelofibrosis; minimal evidence |
| NCT01008462 | Phase 2 | Completed | 16 | Sequential autologous and nonmyeloablative haploidentical transplant with a fludarabine-based regimen |
| NCT00309842 | Phase 2 | Completed | 213 | Cord blood transplant with cyclophosphamide/fludarabine/TBI conditioning in hematologic diseases |
| NCT00056966 | Phase 1/2 | Completed | 24 | CD45 antibody and alemtuzumab conditioning for allogeneic transplant; fludarabine is a component |
| NCT00909948 | Phase 1 | Terminated | 7 | Intentional donor graft rejection after nonmyeloablative transplant; fludarabine indirectly relevant |
| NCT03093168 | Phase 1 | Unknown | 10 | BCMA-targeted T cells; fludarabine used only for lymphodepletion |
| NCT05577000 | Phase 1b | Active, not recruiting | 5 | Anti-BCMA CAR-T in relapsed or refractory myeloma; fludarabine used only for lymphodepletion |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38483213 | 2024 | Phase 1 trial | Am J Clin Oncol | Bortezomib, fludarabine and melphalan, with or without total marrow irradiation, as transplant conditioning in high-risk or refractory myeloma |
| 17310135 | 2007 | Cohort | Bone Marrow Transplant | Fludarabine plus treosulfan conditioning before allogeneic transplant in 34 myeloma patients; reduced-toxicity regimen judged feasible |
| 37701906 | 2023 | Phase 2 | Leuk Res Rep | Split-dose busulfan, fludarabine and post-transplant cyclophosphamide in 2 myeloma and 4 myelofibrosis patients; 1-year overall survival 50% |
| 40972962 | 2025 | Real-world | Transplant Cell Ther | Fludarabine lymphodepletion exposure was associated with toxicities after ide-cel in relapsed or refractory myeloma |
| 17976186 | 2007 | Preclinical | Eur J Haematol | Fludarabine inhibited myeloma cells in vitro and in vivo, with decreased Akt phosphorylation |
| 7781758 | 1995 | Report | Eur J Haematol | Fludarabine in plasma cell leukaemia (no abstract available) |
| 39365257 | 2025 | Cohort | Blood | Standard-of-care cilta-cel in relapsed or refractory myeloma at 16 US centres |
| 38659046 | 2024 | Cohort | J Hematol Oncol | 5-year follow-up of LEGEND-2 BCMA CAR-T therapy |
| 35333600 | 2022 | Cohort | J Clin Oncol | Long-term follow-up of combined BCMA and CD19 CAR-T in myeloma |
| 1415309 | 1992 | Review | Am J Med | Parallels and contrasts between multiple myeloma and chronic lymphocytic leukaemia |
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 89209 | Fludara 10mg Tablet | Strip of 20 tablets | Not available |
| 86414 | Fludara 50mg Injection | Vial of 1 injection | Not available |
| 158531 | Naprobin 50mg Injection | Vial of 1 injection | Not available |
| 89766 | Fludabine 10mg Tablet | Strip of 5 tablets | Not available |
| 90441 | Fludaphos 50mg Injection | Vial of 1 injection | Not available |
Nine valid single-ingredient registrations exist in total. Four more are not listed here: Fludacel, Fludarither, Fludocyte and Lymfuda.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analog) |
| Myelosuppression Risk | High. Significant myelosuppression is a recognised harm (PMID 23787174) |
| Emetogenicity Classification | Low |
| Monitoring Items | CBC with differential, liver and renal function, neurological status |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Published reports also describe severe, sometimes irreversible neurotoxicity at high doses (PMID 7525188) and therapy-related myelodysplastic syndrome or acute myeloid leukaemia after fludarabine combination chemotherapy (PMID 20962860). Please refer to the package insert for full warnings and precautions.
Safety Considerations
- Drug Interactions: Interaction screening returned 100 potential interacting drugs. The listed items include:
- Moderate: metronidazole, rosuvastatin, simvastatin, tinidazole.
- Minor: levofloxacin.
- Unclassified: many others, including cimetidine, amphotericin B, omeprazole, pantoprazole and metformin.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Fludarabine has a well-established role as a lymphodepleting and conditioning agent in myeloma transplant and CAR-T regimens, supported by phase 1 to 3 trials. There is also preclinical evidence of direct antimyeloma activity. However, no trial tests fludarabine as a stand-alone myeloma therapy. Any repurposing should therefore be framed as use within conditioning or lymphodepletion regimens.
To proceed, the following is needed:
- Package insert warnings and contraindications for the Indian products, plus the approved indication text, which is missing for all nine registrations
- Detailed mechanism of action data
- Exposure-toxicity data for fludarabine lymphodepletion, given the toxicity association reported with ide-cel
- Dose adjustment guidance for renal impairment and age
- A neurotoxicity and myelosuppression monitoring plan
- A review of the drug interaction list, since many entries are unclassified
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.